CN112533611A - 19-去甲基c3,3-二取代的c21-n-吡唑基类固醇及其使用方法 - Google Patents

19-去甲基c3,3-二取代的c21-n-吡唑基类固醇及其使用方法 Download PDF

Info

Publication number
CN112533611A
CN112533611A CN201980051843.5A CN201980051843A CN112533611A CN 112533611 A CN112533611 A CN 112533611A CN 201980051843 A CN201980051843 A CN 201980051843A CN 112533611 A CN112533611 A CN 112533611A
Authority
CN
China
Prior art keywords
subject
compound
weeks
dosing regimen
depression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980051843.5A
Other languages
English (en)
Chinese (zh)
Inventor
S.J.卡内斯
J.J.多赫蒂
H.冈杜兹-布鲁斯
J.M.乔纳斯
R.A.拉瑟
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sage Therapeutics Inc
Original Assignee
Sage Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sage Therapeutics Inc filed Critical Sage Therapeutics Inc
Priority to CN202410051762.8A priority Critical patent/CN117959309A/zh
Publication of CN112533611A publication Critical patent/CN112533611A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201980051843.5A 2018-06-12 2019-06-12 19-去甲基c3,3-二取代的c21-n-吡唑基类固醇及其使用方法 Pending CN112533611A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202410051762.8A CN117959309A (zh) 2018-06-12 2019-06-12 19-去甲基c3,3-二取代的c21-n-吡唑基类固醇及其使用方法

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862684155P 2018-06-12 2018-06-12
US62/684,155 2018-06-12
US201962789329P 2019-01-07 2019-01-07
US62/789,329 2019-01-07
US201962841645P 2019-05-01 2019-05-01
US62/841,645 2019-05-01
PCT/US2019/036848 WO2019241442A1 (en) 2018-06-12 2019-06-12 A 19-nor c3,3-disubstituted c21 -n-pyrazolyl steroid and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202410051762.8A Division CN117959309A (zh) 2018-06-12 2019-06-12 19-去甲基c3,3-二取代的c21-n-吡唑基类固醇及其使用方法

Publications (1)

Publication Number Publication Date
CN112533611A true CN112533611A (zh) 2021-03-19

Family

ID=67211854

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201980051843.5A Pending CN112533611A (zh) 2018-06-12 2019-06-12 19-去甲基c3,3-二取代的c21-n-吡唑基类固醇及其使用方法
CN202410051762.8A Pending CN117959309A (zh) 2018-06-12 2019-06-12 19-去甲基c3,3-二取代的c21-n-吡唑基类固醇及其使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202410051762.8A Pending CN117959309A (zh) 2018-06-12 2019-06-12 19-去甲基c3,3-二取代的c21-n-吡唑基类固醇及其使用方法

Country Status (12)

Country Link
US (4) US20210338692A1 (https=)
EP (1) EP3806863A1 (https=)
JP (3) JP2021527092A (https=)
KR (1) KR20210021005A (https=)
CN (2) CN112533611A (https=)
AU (2) AU2019287491B2 (https=)
CA (1) CA3103421A1 (https=)
IL (1) IL279315A (https=)
MA (1) MA52894A (https=)
MX (2) MX2020013557A (https=)
SG (1) SG11202012344RA (https=)
WO (1) WO2019241442A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2806877B2 (en) 2012-01-23 2025-01-29 Sage Therapeutics, Inc. Neuroactive steroid formulations comprising a complex of allopregnanolone and sulfobutyl ether beta-cyclodextrin
CA2882708A1 (en) 2012-08-21 2014-02-27 Sage Therapeutics, Inc. Methods of treating epilepsy or status epilepticus
KR102396328B1 (ko) 2013-04-17 2022-05-10 세이지 테라퓨틱스, 인크. 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드 및 그의 사용 방법
US10246482B2 (en) 2014-06-18 2019-04-02 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
WO2016082789A1 (en) 2014-11-27 2016-06-02 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
EP3504189A1 (en) 2016-08-23 2019-07-03 Sage Therapeutics, Inc. A crystalline 19-nor c3, 3-disubstituted c21-n-pyrazolyl steroid
MA51046A (fr) 2017-12-08 2021-03-17 Sage Therapeutics Inc Dérivés de 21-[4-cyano-pyrazol-1-yl]-19-nor-pregan-3. alpha-ol-20-one deutérés pour le traitement de troubles du snc
KR20220112803A (ko) * 2019-12-05 2022-08-11 세이지 테라퓨틱스, 인크. 19-nor c3,3-이치환된 c21-n-피라졸릴 스테로이드 및 그의 사용 방법
EP4125921A1 (en) 2020-03-25 2023-02-08 Sage Therapeutics, Inc. Use of agents for treatment of respiratory conditions
KR20230041049A (ko) * 2020-07-20 2023-03-23 세이지 테라퓨틱스, 인크. 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드의 제형 및 이의 사용 방법
KR20230136599A (ko) * 2021-01-28 2023-09-26 세이지 테라퓨틱스, 인크. 성 기능장애의 치료를 위한 신경활성 스테로이드의용도
US20240245711A1 (en) * 2021-03-17 2024-07-25 Sage Therapeutics, Inc. A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid for the treatment of major depressive disorder
WO2022232504A1 (en) * 2021-04-29 2022-11-03 Sage Therapeutics, Inc. 19-nor c3,3-disubstituted c21 -n-pyrazolyl steroid for use in treating major depressive disorder and postpartum depression
EP4329769A1 (en) * 2021-04-29 2024-03-06 Sage Therapeutics, Inc. Neuroactive steroid for use in treating major depressive disorder and postpartum depression in a lactating female
IL315023A (en) * 2022-02-16 2024-10-01 Sage Therapeutics Inc Neuroactive steroids for treatment of cns-related disorders
WO2025175214A1 (en) * 2024-02-16 2025-08-21 Engrail Therapeutics, Inc. Methods of treating generalized anxiety disorder

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105339381A (zh) * 2013-04-17 2016-02-17 萨奇治疗股份有限公司 19-去甲c3,3-二取代的c21-n-吡唑基类固醇及其使用方法
CN107106574A (zh) * 2014-09-08 2017-08-29 萨奇治疗股份有限公司 神经活性类固醇、组合物及其用途
WO2018039378A1 (en) * 2016-08-23 2018-03-01 Sage Therapeutics, Inc. A crystalline 19-nor c3, 3-disubstituted c21-n-pyrazolyl steroid

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ME03809B (me) * 2014-10-16 2021-04-20 Sage Therapeutics Inc KOMPOZICIJE I POSTUPCI ZA LEČENJE POREMEĆAJA CNS-a
KR20240157128A (ko) * 2016-03-08 2024-10-31 세이지 테라퓨틱스, 인크. 신경활성 스테로이드, 조성물, 및 그의 용도
WO2019051264A1 (en) * 2017-09-07 2019-03-14 Sage Therapeutics, Inc. NEUROACTIVE STEROIDS AND METHODS OF USE

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105339381A (zh) * 2013-04-17 2016-02-17 萨奇治疗股份有限公司 19-去甲c3,3-二取代的c21-n-吡唑基类固醇及其使用方法
CN107106574A (zh) * 2014-09-08 2017-08-29 萨奇治疗股份有限公司 神经活性类固醇、组合物及其用途
WO2018039378A1 (en) * 2016-08-23 2018-03-01 Sage Therapeutics, Inc. A crystalline 19-nor c3, 3-disubstituted c21-n-pyrazolyl steroid

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GABRIEL MARTINEZ BOTELLA等: ""Neuroactive Steroids. 2.3α-Hydroxy-3β-methyl-21-(4-cyano-1H-pyrazol-1\'-yl)-19-nor-5β-pregnan-20-one(SAGE-217):A Clinical Next Generation Neuroactive Steroid Positive Allosteric Modulator of the (γ-Aminobutyric Acid)A Receptor"", 《J MED CHEM》, vol. 60, no. 18 *
H GUNDUZ-BRUCE等: ""SAGE-217 insubjects with major depressive disorder :efficacy and safety results fromen-tabel Part A of a phase 2A study"", 《EUROPEAN NEUROPSYCHOPHARMACOLOGY》, pages 1 *

Also Published As

Publication number Publication date
JP2024028849A (ja) 2024-03-05
CN117959309A (zh) 2024-05-03
JP2025108553A (ja) 2025-07-23
MX2025000166A (es) 2025-03-07
AU2019287491B2 (en) 2025-05-15
IL279315A (en) 2021-01-31
US20210338692A1 (en) 2021-11-04
KR20210021005A (ko) 2021-02-24
US20250339447A1 (en) 2025-11-06
WO2019241442A1 (en) 2019-12-19
MA52894A (fr) 2021-04-21
JP2021527092A (ja) 2021-10-11
TW202005653A (zh) 2020-02-01
EP3806863A1 (en) 2021-04-21
SG11202012344RA (en) 2021-01-28
CA3103421A1 (en) 2019-12-19
US20200113917A1 (en) 2020-04-16
AU2025217363A1 (en) 2025-09-04
MX2020013557A (es) 2021-05-27
AU2019287491A1 (en) 2021-01-07
US20220323462A1 (en) 2022-10-13

Similar Documents

Publication Publication Date Title
CN112533611A (zh) 19-去甲基c3,3-二取代的c21-n-吡唑基类固醇及其使用方法
TW202133863A (zh) １９—ｎｏｒ—ｃ３，３—二取代—ｃ２１—ｎ—吡唑基類固醇及使用其之方法
CN114929209A (zh) 肌萎缩侧索硬化的治疗
US20240216395A1 (en) 19-nor c3,3-disubstituted c21 -n-pyrazolyl steroid for use in treating major depressive disorder and postpartum depression
KR20240148425A (ko) Cns-관련 장애의 치료를 위한 신경활성 스테로이드
CN114767646A (zh) 一种胃滞留的胆汁酸螯合剂剂型的效果
CN113825510A (zh) 使用氘化右美沙芬和奎尼丁治疗精神分裂症的阴性症状的方法
Sommer et al. Creative-dynamic image synthesis: a useful addition to the treatment options for impotence
RU2851101C2 (ru) 19-nor с3,3-замещенный с21-n-пиразолилстероид и способы его применения
JP2024540104A (ja) アルツハイマー病に関連する激越を治療する方法
Powell et al. average recipients per month using pharmacy benefits, and an average paid per prescription of $131.82. Cost Management Analysis: L. Thomas reported an average cost per claim of $130.43 for September 2021 and compared previous months contained in the table. From the 3" Ouarter 2021 Drug Analysis
KR20250153297A (ko) 샤르코-마리-투스병의 치료를 위한 조성물 및 방법
CN117580581A (zh) 用于治疗重度抑郁障碍和产后抑郁症的19-去甲c3,3-二取代的c21-n-吡唑基类固醇
York et al. In men who have sex with men, does intermittent pre-exposure prophylaxis demonstrate high efficacy in preventing HIV transmission?
HK40060751A (en) Methods of treating negative symptoms of schizophrenia using deuterated dextromethorphan and quinidine
Bukhari Pharmacy Registration Assessment Questions

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20210319